Skip to content
DataLookout
Menu

NCT07738614

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 9 words
    • Enrollment closed, study ongoing
    • Site details revised at 2 of 2 sites
  2. Notable Recruitment opened
    • Start date changed from estimate of Jul 2026 to Jul 31, 2026
    • Site details revised at 2 of 2 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Acetaminophen Area Under the Concentration Versus Time Curve (AUC)
Timeframe: Baseline to Day 65
Acetaminophen Maximum Observed Concentration (Cₘₐₓ)
Timeframe: Baseline to Day 65
Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ)
Timeframe: Baseline to Day 65

Secondary (2)

Eloralintide AUC
Eloralintide Cₘₐₓ

Arms and interventions

Eloralintide Cohort 1Experimental

Eloralintide administered subcutaneously (SC)

Eloralintide Cohort 2Experimental

Eloralintide administered SC

Eloralintide Cohort 3Experimental

Eloralintide administered SC

Eloralintide Cohort 4Experimental

Eloralintide administered SC

PlaceboPlacebo comparator

Placebo administered SC

Drugs: Eloralintide, Placebo, Acetaminophen

Sites

2 sites in 2 countries

Singapore 1, United States 1